Project Grant R21EB038806
- The National Institute of Biomedical Imaging and Bioengineering awarded Massachusetts General Hospital $247,500 on June 6, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a miniaturized scanning light endoscope with no moving parts for high-speed three-dimensional deep imaging in live biological systems. The recipient will leverage potassium tantalate niobite (KTN) crystal technology to create a compact optical...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Trustees of Boston University $232,550 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a mid-infrared photothermal fiber probe for label-free imaging and biomolecular composition analysis in endoscopic applications. The project will develop a fiber-based probe that integrates mid-infrared photothermal imaging with...
- The National Cancer Institute awarded The Johns Hopkins University $399,829 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop Vascular Expansion Microscopy (VascExM), a method for high-resolution optical imaging of brain vasculature at endothelial cell scale on standard, diffraction-limited microscopes. The work addresses the need for sub-micron vascular imaging in preclinical and clinical neuropathology samples. The recipient will develop...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Texas at Arlington $378,411 on April 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop super-resolution tomographic imaging technology for deep tissue visualization. The project aims to overcome diffraction limits inherent in existing super-resolution imaging modalities—including super-resolution fluorescence...
- The National Institute of Biomedical Imaging and Bioengineering awarded Emai LLC $306,872 on August 20, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop an advanced microwave imaging system for early detection of breast cancer. The award is classified as a Project Grant. The recipient will address two key technical barriers in microwave breast imaging (MBI) that have delayed commercialization. Existing...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Johns Hopkins University $621,956 on August 12, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop artificial intelligence algorithms that detect very small pancreatic, hepatobiliary, and upper gastrointestinal cancers in computed tomography scans. The research addresses the late-stage detection problem in these disease categories, which...
- The National Institute of Biomedical Imaging and Bioengineering awarded Brigham & Women's Hospital Inc. $1,583,125 on May 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements. The recipient will develop an interventional drug response assay (IDRA) device to enable biopsy-based phase-0 measurements...
- The National Cancer Institute awarded William Marsh Rice University $106,677 on January 11, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop an automated multimodal, multiscale algorithm for cervical cancer screening in low- and middle-income countries. The funded work pursues three specific aims: design a multimodal image registration algorithm to spatially correlate and combine widefield colposcope images of the cervix acquired after staining with acetic acid and...
- The National Institute of Biomedical Imaging and Bioengineering, a component of the Department of Health and Human Services National Institutes of Health, awarded $184,063 to the University of Texas at San Antonio on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds development of forced-dimerization activated photoacoustic aptamer switch sensors (FDA-PASS), optical probes designed to enable...
- The National Cancer Institute awarded the University of Maryland, College Park $663,736 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a multimodal KeyScope laparoscope that increases access to laparoscopic surgery in underserved settings. The project addresses the gap between the clinical standard of laparoscopic surgery—which reduces post-surgical mortality and morbidity compared to open surgery—and its limited availability in rural...
The National Institute of Biomedical Imaging and Bioengineering awarded Rice University $182,736 on August 3, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a multi-modal, multi-depth, high-resolution micro-endoscope (M3D-HRME) for early cancer detection. The project pursues feasibility studies to create optical micro-endoscopic devices capable of detecting early-stage cancer by combining advances in fabrication technologies to manufacture integrated miniature multi-lens objectives paired with high-resolution micro-endoscope imaging. The M3D-HRME device integrates multiple mini-objectives along waveguide structures using 2-photon polymerization additive manufacturing, with mini-objectives printed directly on polished imaging fiber bundles. The device will provide front and side viewing capability for imaging internal wall structures such as the cervical os. The probe delivers 2-micron resolution fluorescence imaging of outer tissue morphology and 15–20 microns resolution dark-field imaging of microvasculature at depths of 70–140 microns below the tissue surface. By detecting angiogenesis pattern changes associated with dysplasia alongside nuclear morphology changes, the M3D-HRME will enable real-time mosaicked complementary imaging of both tissue morphology and microvasculature. Work is performed in Houston, Texas. The project runs through July 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $182.7k | 8/3/26 |